Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000919574-25-001296
Filing Date
2025-02-13
Accepted
2025-02-13 20:15:31
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 11348
2 d11604773_ex-99a.htm EX-99 4967
3 d11604773_ex-99b.htm EX-99 694
  Complete submission text file 0000919574-25-001296.txt   18826
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130 (858) 500-8800
Kura Oncology, Inc. (Subject) CIK: 0001422143 (see all company filings)

EIN.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-83933 | Film No.: 25622508
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 540 MADISON AVENUE 7TH FLOOR NEW YORK NY 10022
Business Address 540 MADISON AVENUE 7TH FLOOR NEW YORK NY 10022 2127025204
SUVRETTA CAPITAL MANAGEMENT, LLC (Filed by) CIK: 0001569064 (see all company filings)

EIN.: 453704500 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A